Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HIV-1 subtype-specific drug resistance on dolutegravir-based antiretroviral therapy: protocol for a multicentre longitudinal study (DTG RESIST).
Egger M, Sauermann M, Loosli T, Hossmann S, Riedo S, Beerenwinkel N, Jaquet A, Minga A, Ross JL, Giandhari J, Kouyos R, Lessells R. Egger M, et al. Among authors: loosli t. medRxiv [Preprint]. 2024 May 24:2024.05.23.24307850. doi: 10.1101/2024.05.23.24307850. medRxiv. 2024. Update in: BMJ Open. 2024 Aug 21;14(8):e085819. doi: 10.1136/bmjopen-2024-085819 PMID: 38952780 Free PMC article. Updated. Preprint.
HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis.
Loosli T, Hossmann S, Ingle SM, Okhai H, Kusejko K, Mouton J, Bellecave P, van Sighem A, Stecher M, d'Arminio Monforte A, Gill MJ, Sabin CA, Maartens G, Günthard HF, Sterne JAC, Lessells R, Egger M, Kouyos RD. Loosli T, et al. Lancet HIV. 2023 Nov;10(11):e733-e741. doi: 10.1016/S2352-3018(23)00228-X. Epub 2023 Oct 10. Lancet HIV. 2023. PMID: 37832567 Free PMC article.
sHIV-1 drug resistance in people on dolutegravir-based ART: Collaborative analysis of cohort studies.
Loosli T, Hossmann S, Ingle SM, Okhai H, Kusejko K, Mouton J, Bellecave P, van Sighem A, Stecher M, d'Arminio Monforte A, Gill MJ, Sabin CA, Maartens G, Günthard HF, Sterne JAC, Lessells R, Egger M, Kouyos R. Loosli T, et al. medRxiv [Preprint]. 2023 Apr 5:2023.04.05.23288183. doi: 10.1101/2023.04.05.23288183. medRxiv. 2023. Update in: Lancet HIV. 2023 Nov;10(11):e733-e741. doi: 10.1016/S2352-3018(23)00228-X PMID: 37066200 Free PMC article. Updated. Preprint.
Frequency matters: comparison of drug resistance mutation detection by Sanger and next-generation sequencing in HIV-1.
Balakrishna S, Loosli T, Zaheri M, Frischknecht P, Huber M, Kusejko K, Yerly S, Leuzinger K, Perreau M, Ramette A, Wymant C, Fraser C, Kellam P, Gall A, Hirsch HH, Stoeckle M, Rauch A, Cavassini M, Bernasconi E, Notter J, Calmy A, Günthard HF, Metzner KJ, Kouyos RD. Balakrishna S, et al. Among authors: loosli t. J Antimicrob Chemother. 2023 Mar 2;78(3):656-664. doi: 10.1093/jac/dkac430. J Antimicrob Chemother. 2023. PMID: 36738248
Quantifying and Predicting Ongoing Human Immunodeficiency Virus Type 1 Transmission Dynamics in Switzerland Using a Distance-Based Clustering Approach.
Labarile M, Loosli T, Zeeb M, Kusejko K, Huber M, Hirsch HH, Perreau M, Ramette A, Yerly S, Cavassini M, Battegay M, Rauch A, Calmy A, Notter J, Bernasconi E, Fux C, Günthard HF, Pasin C, Kouyos RD; Swiss HIV Cohort Study. Labarile M, et al. Among authors: loosli t. J Infect Dis. 2023 Feb 14;227(4):554-564. doi: 10.1093/infdis/jiac457. J Infect Dis. 2023. PMID: 36433831 Free article.
12 results